Far‑infrared therapy improves ankle brachial index in hemodialysis patients with peripheral artery disease

October 26, 2019

Abstract

Ankle brachial index (ABI) is a diagnostic tool for peripheral artery disease (PAD), which is an important issue in hemodialysis

(HD) patients. We enrolled 198 maintenance HD patients in this study. PAD is defined as ABI ≤ 0.90. Only PAD

patients received far-infrared (FIR) therapy using the WS TY101 FIR emitter for 40 min during each HD session, three

times weekly for 6 months. The ABI was measured at the bilateral lower extremities for 4 times [pre-dialytic timing (0 min)

and 40 min after the initiation of HD session at both day 0 and 6 months after the FIR therapy]. The primary outcome

is the change in ABI. There were 51 out of 198 patients with PAD. In comparison with the period without FIR therapy

in the 51 PAD patients, 6 months of FIR therapy significantly improved the ABI of the right/left side for 0 min (from

0.77 ± 0.19 to 0.81 ± 0.20, p = 0.027/0.79 ± 0.20 to 0.81 ± 0.17, p = 0.049), 40 min during HD (from 0.73 ± 0.23 to 0.83 ± 0.19,

p < 0.001/from 0.77 ± 0.21 to 0.83 ± 0.18, p < 0.001), and the incremental change between 0 and 40 min (from − 0.04 ± 0.14

to 0.05 ± 0.13, p = 0.007/from − 0.05 ± 0.13 to 0.03 ± 0.11, p = 0.012), respectively. In conclusion, the application of FIR

therapy for 40 min, three times weekly for 6 months, has improved the ABI of both lower extremities, thus providing a new

strategy of PAD treatment in HD patients.

-Heart Vessels (2019) 34: 435-441

Want to know more?



Contact us for more detail


Learn more
Questions to FIRAPY
May 23, 2025
We’re excited to announce that FIRAPY will be exhibiting at the 62nd ERA Congress in Vienna from June 4–7, 2025 ! 📍 Booth No.: X1.200 📅 June 4–7, 2025 📍 Austria Center Vienna This marks FIRAPY’s first European event since the COVID-19 pandemic , making it a special occasion for us to reconnect with partners and professionals across the continent. This year’s congress theme, “Game Changers in Nephrology,” aligns perfectly with FIRAPY’s mission to enhance dialysis care through innovative vascular access management. We look forward to seeing old friends and new collaborators who share our commitment to improving outcomes for dialysis patients. Whether you're already using FIRAPY or exploring its clinical potential, we warmly invite you to visit our booth and connect with our team.  Let’s explore how far-infrared therapy is transforming the future of vascular access—together.
May 23, 2025
From February 28 to March 1, FIRAPY was honored to participate in Dialysis Weekend 2024 in Pattaya, Thailand, at the invitation of our valued partner K2 Thailand . This annual event, hosted by the Nephrology Society of Thailand ( event site ), is a key gathering for nephrology professionals across the country. This occasion marked a milestone for K2 Thailand, as their entire dialysis sales team made their first collective public appearance alongside FIRAPY. The team’s strong presence and professionalism drew significant attention from both clinicians and industry attendees, highlighting the growing interest in FIRAPY's role in dialysis care. A special highlight of the event was the visit from Dr. Suki , a well-known figure in the international nephrology community ( WCN profile ). Dr. Suki stopped by the K2 booth to personally show support and encouragement to the team, reinforcing the collaboration and shared mission of improving vascular access outcomes for dialysis patients. 
December 2, 2024
Meet FIRAPY at Booth i1115a!
More Posts